MYBIOPASSPORT
Mybiopassport.com, the platform set-up by CoreMedica Europe, a Swiss biotechnology company with their Swissmedic authorized laboratory based in Geneva, announced today the launch of their “Nutritional Profile” and “Sport Performance Profile” tests, which will complement their current “Immunity Profile” and “COVID-19” tests
Mybiopassport proposes at-home blood collection tests to help anyone become the “heroes of their own health” . Individuals can now collect only a few drops of blood at their homes and send their samples by regular prepaid mail to the company’s authorized laboratory located in Geneva, Switzerland, to determine the levels of key biomarkers known to support sport performance, a healthy nutrition, and the immune system. The tests can be ordered at www.mybiopassport.com and personalized results are delivered to each individual on the online portal through a simple sign-up procedure.
The purposes of these tests are as follows :
- Nutritional – A tool informing the client of their current nutritional status based on past habits and providing personalized recommendations on how to correct any deficiencies or excesses through nutrition. The first of its kind, this test provides information about the levels of micronutrients belonging to all four classes of essential micronutrients, namely vitamins, minerals, fatty acids and amino acids. These are all linked to specific bodily functions (fatigue, sleep, anxiety, etc.) making this test the most comprehensive and informative on the market.
- Sport Performance – A tool developed to help amateur and professional athletes determine if their performance related biomarkers are at their optimal levels to allow them to perform at their best. All the biomarkers tested are linked to specific sport related functions, such as recovery , muscle growth, energy delivery, or even as specific as exercise induced joint pain.
- Immunity - The COVID-19 & Immunity Profile, powered by Mybiopassport, lets clients know if they were previously infected by the SARS-CoV-2 virus through the development of specific antibodies. More importantly, the Immunity Profile test also delivers actionable nutritional recommendations based on a set of key biomarkers known to support the immune system, including vitamin D, zinc and magnesium.
It is now widely accepted that the first step towards a healthy body is good nutrition. Indeed, multiple studies have shown that the risks of developing cardiovascular disease, diabetes, and even dementia are strongly linked to long-term nutritional habits. Recent scientific reports and publications have highlighted the role of nutrition, optimal micronutrient status and a well-functioning immune system as a modifiable factor in reducing the risk of viral infections and their severity. These publications highlight the key role of a good nutritional status for a well-functioning immune system.
Mybiopassport’s mission is clearly to democratize access to specific health-related information and to give people the means to not only understand, but also act on their health through nutrition and lifestyle. They firmly believe in individual empowerment and that the access to personalized health information is the first step towards preventing potential health issues.
Mybiopassport relies on a unique technology in the personalized analysis of biological data on three main axes:
- Pre-analytical with the easy collection of a few drops of blood anywhere, at any time and by anyone,
- Analytical, with the measurement of an unprecedentedly large number of phenotypic biomarkers, via a unique know-how developed over several years,
- Post-analytical, providing not only a scientific result, but personalized recommendations based on a patented technology applied in several fields, such as immunity, nutrition, sport, longevity and anti-aging.
Individuals can now collect a few drops of blood from the comfort and safety of their homes and send their samples by prepaid regular mail to Mybiopassport’s laboratory in Geneva.
The Nutritional, Sport Performance and Immunity tests can be ordered at www.mybiopassport.com and personalized results are delivered to each individual on the online portal with test results reviewed by health professionals.
About CoreMedica Europe:
As a background, BioKaizen, founded in Switzerland and born from developers of the athlete biological passport to detect drug use for the World Anti-Doping Agency and the International Olympic Committee, has developed a mass spectrometry technology platform to identify a person’s nutritional profile using dried blood. Following the merger with BioKaizen in 2018 and its recent acquisition by Swiss Medical Group Holding Luxembourg SA, CoreMedica Europe expanded its offering globally to include personalized nutrition and sport performance information that empowers customers with information to help actively manage their health.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210204006231/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
